Indinavir Sulfate

CHEMBL1735 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
711.9 g/mol
LogP
Phase
4

This sulfate salt of indinavir is the pharmaceutical formulation of this HIV protease inhibitor used in combination antiretroviral regimens. It blocks the HIV protease enzyme, preventing the assembly of mature, infectious HIV particles. It must be taken with careful attention to hydration due to the risk of kidney stones.

분자량

711.9000 g/mol

TPSA

201.00 Ų

치료 영역

작용 기전

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O.O=S(=O)(O)O

InChI

InChI=1S/C36H47N5O4.H2O4S/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43;1-5(2,3)4/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45);(H2,1,2,3,4)/t28-,29+,31+,32-,33+;/m1./s1

Molecular Formula

C36H49N5O8S

HBD / HBA

6 / 11

회전 가능 결합

12

무거운 원자

50

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This sulfate salt of indinavir is the pharmaceutical formulation of this HIV protease inhibitor used in combination antiretroviral regimens. It blocks the HIV protease enzyme, preventing the assembly of mature, infectious HIV particles. It must be taken with careful attention to hydration due to the risk of kidney stones.

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Yes, Indinavir Sulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1735. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5462355. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.